Skip to main content

Immutep Health Care
Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
Register to track IMM and receive email alerts.

Short Interest

ASIC data, 17 Aug 2026

% Shorted

2.71% 0.01
vs 2.71% prior report

Most Shorted Rank

123rd
of 697 shorted ASX stocks

Peak Short

3.74%
Jul 2026

Days to Cover

3.8
at 50d avg vol
View full short position history →
Subject
MediaBot
IMM Article: Immutep raises $100m and signs with Merck on ‘blockbuster’ drug

MediaBot
IMM Article: Biotech Immutep seeks $102 million, taps three brokers

MediaBot
IMM Article: Perennial fundie’s top small-cap healthcare picks

StockBot
IMM Ann: Application for quotation of securities - IMM

StockBot
IMM Ann: US patent granted for Efti with PD-1 pathway inhibitor

StockBot
IMM Ann: Immutep completes underwritten retail entitlement offer

StockBot
IMM Ann: Immutep granted US patent for IMP761 agonist LAG-3 antibody

StockBot
IMM Ann: Change in substantial holding from IFL

StockBot
IMM Ann: Change in substantial holding

StockBot
IMM Ann: Change in substantial holding

StockBot
IMM Ann: Becoming a substantial holder

StockBot
IMM Ann: Cleansing Notice

StockBot
IMM Ann: Application for quotation of securities - IMM

StockBot
IMM Ann: Immutep letter to ineligible shareholders

StockBot
IMM Ann: Immutep retail entitlement offer booklet

StockBot
IMM Ann: Positive final data in 2nd line head and neck cancer at ASCO

MediaBot
IMM Article: Fundies pile into Immutep $80m raise

StockBot
IMM Ann: Immutep completes institutional pro-rata offer & placement

StockBot
IMM Ann: Change in substantial holding

MediaBot
IMM Article: Immutep in $80m raise; Bells, Jefferies and Wilsons on ticket

StockBot
IMM Ann: Cleansing Notice

StockBot
IMM Ann: Proposed issue of securities - IMM

StockBot
IMM Ann: Immutep Capital Raising Presentation

StockBot
IMM Ann: A$80 million fully underwritten equity raising

StockBot
IMM Ann: Trading Halt

StockBot
IMM Ann: Charles River Laboratories to run IMP761 Toxicology Study

StockBot
IMM Ann: Publication of Abstracts for ASCO 2023 Annual Meeting

StockBot
IMM Ann: 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial

StockBot
IMM Ann: Promising New Data in 1st line NSCLC from INSIGHT-003 Trial

StockBot
IMM Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC

StockBot
IMM Ann: FDA supportive of Efti registrational trial in lung cancer

StockBot
IMM Ann: Change of Director's Interest Notice - R Howard

StockBot
IMM Ann: Approval to start Efti & Bavencio trial in urothelial cancer

StockBot
IMM Ann: Immutep Quarterly Activities Report and Appendix 4C

StockBot
IMM Ann: Immutep to announce new TACTI-002 data at ASCO 2023

StockBot
IMM Ann: Immutep appoints Dr Florian Vogl as Chief Medical Officer

StockBot
IMM Ann: Response to ASX Aware Query

StockBot
IMM Ann: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma

StockBot
IMM Ann: Notification of cessation of securities - IMM

MediaBot
IMM Article: ASX to edge higher; Newmont increases bid for Newcrest

StockBot
IMM Ann: Appendix 3Z - Lucy Turnbull

StockBot
IMM Ann: Appendix 3X - Lis Boyce

StockBot
IMM Ann: Immutep Announces Changes to the Board

StockBot
IMM Ann: Positive Final Data in 2nd Line Metastatic NSCLC Patients

StockBot
IMM Ann: Change in substantial holding

StockBot
IMM Ann: Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC

StockBot
IMM Ann: Abstract accepted for ESMO's European Lung Cancer Congress

StockBot
IMM Ann: Initiation of Ph 2/3 Trial for Metastatic Breast Cancer

StockBot
IMM Ann: Half Yearly Report and Accounts

StockBot
IMM Ann: Enrolment Target Reached for INSIGHT-003 Trial in NSCLC

Register to track IMM and receive email alerts.

Similar Companies

CSL ...
CSL
Clinuvel Pharmaceuticals
CUV
Imugene
IMU
Mesoblast
MSB
Opthea
OPT
Paradigm Biopharmaceuticals
PAR
PYC Therapeutics
PYC
Race Oncology
RAC
Telix Pharmaceuticals
TLX